Sustained benefit of stenting chronic coronary occlusion: long-term clinical follow-up of the Stenting in Chronic Coronary Occlusion (SICCO) study

Objectives. This study assessed the long-term clinical outcome of stenting chronic occlusions. Background. In the Stenting in Chronic Coronary Occlusion (SICCO) study, patients were randomized to additional stent implantation (n = 58) or not (n = 59) after successful recanalization and dilation of chronic coronary occlusion. Palmaz-Schatz stents were used with full anticoagulation. The previously published 6-month angiographic follow-up results showed reduction of the restenosis rate from 74% to 32%. Methods. The primary end point was the occurrence of major adverse cardiac events (cardiac death, lesion-related acute myocardial infarction, repeat lesion-related revascularization or angiographic documentation of reocclusion). Results. Late clinical follow-up was obtained in all patients at 33 ± 6 months. Major adverse cardiac events occurred in 14 patients (24.1%) in the stent group compared with 35 patients (59.3%) in the percutaneous transluminal coronary angioplasty (PTCA) group (odds ratio 0.22, 95% confidence interval 0.10 to 0.49, p = 0.0002). Target vessel revascularization (including failed PTC attempts) was performed in 24% of the stent group and in 53% of the PTC group (p = 0.002). There were no events in the stent group after 8 months, whereas events continued to occur in the PTC group. By multivariate analysis, allocation to the PTC group, left anterior descending coronary artery lesion and lesion length were significantly related to the development of major adverse cardiac events. Conclusions. These dat demonstrate the long-term safety and clinical benefit of stenting recanalized chronic occlusions. There is continued risk of late clinical events related to nonstented lesions. Implantation of an intracoronary stent should therefore be considered after successful opening of chronic coronary occlusion.